fda drug safety communication naion semaglutide 2025 Wegovy HD Alerts, Recalls & Warnings Novo Nordisk Seeks FDA Approval

The other drugs included SGLT2 inhibitors, which decrease blood sugar levels by preventing glucose from being absorbed in the kidneys, and DPP4 inhibitors, which help the pancreas release insulin

10.1056/NEJMoa2313917

Bariatric surgery should be considered for eligible patients (typically BMI 40 kg/m or 35 kg/m with comorbidities) who have not achieved or maintained sufficient weight loss with medications and lifestyle interventions

Stopping semaglutide entirely leads to weight regain in the majority of cases

Obesity is a chronic condition that often requires long-term management, and many patients benefit from continued treatment to maintain weight loss and manage related health conditions

Hims & Hers' weight loss business continues to be a major focus for the company, and that segment is on pace to bring in $725 million in revenue in 2025, Yemi Okupe, Hims & Hers' chief financial officer, said during the Q3 call with investors in early November